To evaluate generalized myasthenia gravis (gMG) treatment patterns and healthcare resource utilization (HCRU) in adult patients who initiated rozanolixizumab in the USA.

Rozanolixizumab is a neonatal fragment crystallizable receptor blocker approved for the treatment of adults with anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody-positive gMG.

This retrospective, non-interventional cohort study used de-identified claims data from Komodo Healthcare Map^® (July 1, 2022  to March 31, 2025). Eligible patients were aged ≥18 years with an MG diagnosis, ≥1 rozanolixizumab medical/pharmacy claim and continuous enrollment/plan coverage for 12 months before index date (first rozanolixizumab treatment). The baseline period comprised the 12 months prior to index date; the follow-up period was from the day after index date to last enrollment date. Treatments for MG, including rozanolixizumab, and HCRU were assessed at baseline and during follow-up.

Overall, 719 patients were included, with mean (SD) age of 62.8 (16.0) years. The most common MG treatments were acetylcholinesterase inhibitors (baseline: 68.3%; follow-up: 54.1%) and corticosteroids (baseline: 61.6%; follow-up: 40.5%). Of 386 patients with baseline corticosteroid use and ≥3 months’ follow-up, 29.0% (n=112) tapered their dose by ≥5 mg and 29.3% (n=113) discontinued corticosteroids during follow-up.  For 287 patients with ≥365 days since rozanolixizumab initiation, mean number of treatment cycles started in Year 1 was 2.9. Overall MG-related HCRU incidence rates per 100 person-years decreased from 88.0 during baseline to 82.9 during follow-up, and were 86.2 vs 80.8  for outpatient, 25.6 vs 17.3 for inpatient and 24.9 vs 14.0 for emergency room visits.